BioSpace News Archive

Audentes Therapeutics , an Astellas genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold for the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy (XLMTM). XLMTM is a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death. “We are grateful for t

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biote

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) today announced that it received a waiver letter from SWK Funding LLC (“SWK”) related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus. All other terms and conditions in the SWK loan agreement remain unchanged. About Acerus Acerus Pharmaceuticals Corporation is a Canadian-based

COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure Phase 2/3 clinical trials by COVAXX t

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 39 th Annual J.P. Morgan Healthcare Conference. M

Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced it has entered into definitive agreements with investors for the purchase and sale of 14,444,444 shares of its common stock at a purchase price of $0.45 per share in a registered direct offering.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that on December 24, 2020, the Company received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has cured the bid price deficiency and has regained full compliance with all applicable cr

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, has now completed treatment as well as the required two-week follow up. The Company announced positive tren

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced that it has filed its quarterly reports for 2020 to become current with OTC Markets. BioStem’s Chief Executive Officer, Jason Matuszewski, commented, “The filing of our 2020 quarterly reports not only marks a key milestone for BioStem, but al

Core One Labs Inc. (CSE:COOL), (OTC:CLABF), (Frankfurt:LD62), (WKN:A14XHT) is pleased to announce that, further to its press release of October 7, 2020, it has entered into a definitive share purchase agreement dated December 23, 2020, for the acquisition of all of the outstanding share capital of Vocan Biotechnologies Inc.